Automated Summary
Key Facts
The Competition Tribunal of South Africa unconditionally approved the large merger between RMB Ventures Eight Proprietary Limited and Bopa Moruo Fund II Proprietary Limited acquiring a percentage of Icon Oncology Holdings Proprietary Limited's issued share capital. Post-merger, the acquiring firms will exercise joint control over Icon Holdings. The transaction involves private equity investors acquiring a stake in a South African cancer care provider. The Tribunal concluded no horizontal or vertical overlaps exist between the merging parties, and the merger is unlikely to substantially lessen competition in any market. The public interest assessment noted a positive effect on promoting a greater spread of ownership by historically disadvantaged persons (HDPs).
Issues
- The Tribunal evaluated public interest factors, including employment (no merger-specific job losses) and ownership spread. Pre-merger, Bopa Moruo Group is 100% HDP-owned, while RMB Ventures and FirstRand have partial HDP ownership. Post-merger, the Target Group is estimated to have increased HDP ownership, positively impacting ownership distribution. No significant employment concerns were identified.
- The Competition Tribunal assessed whether the merger between RMB Ventures and Bopa Moruo to acquire Icon Oncology Holdings would substantially lessen competition. The evaluation found no horizontal or vertical overlaps in the merging parties' activities, concluding the transaction is unlikely to harm competition in any relevant market.
Holdings
The Competition Tribunal of South Africa unconditionally approved the large merger between RMB Ventures Eight Proprietary Limited and Bopa Moruo Fund II Proprietary Limited to acquire Icon Oncology Holdings Proprietary Limited. The Tribunal found no horizontal or vertical overlaps in the activities of the merging parties, and the transaction is unlikely to substantially prevent or lessen competition in any relevant market. Additionally, the merger does not raise public interest concerns, including employment impacts or ownership spread issues, and is expected to promote greater HDP ownership.
Remedies
The Competition Tribunal unconditionally approved the large merger between RMB Ventures Eight Proprietary Limited and Bopa Moruo Fund II Proprietary Limited to acquire a percentage of the issued share capital of Icon Oncology Holdings Proprietary Limited. The approval is unconditional, with no requirements or restrictions imposed.
Judge Name
- A. Ndoni
- L. Mncube
- A. Kessery
Passage Text
- The proposed transaction is unlikely to substantially prevent or lessen competition in any relevant market and does not raise any public interest concerns.
- There are no horizontal overlaps between the activities of the merging parties.
- On 28 February 2024, the Competition Tribunal unconditionally approved the large merger in which RMB Ventures Eight Proprietary Limited and Bopa Moruo Fund II Proprietary Limited will acquire a percentage of the issued share capital of Icon Oncology Holdings Proprietary Limited.